MD Anderson, Exscientia collaborate to develop oncology treatments using AI

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT Southwestern published in Nature.

June 13, 2025

Vol.51 No.23

Drugs & Targets

SU2C, SandboxAQ collaborate to accelerate treatment innovation

Stand Up To Cancer and SandboxAQ announced a collaboration that brings SandboxAQ’s Large Quantitative Models to SU2C-funded cancer research projects.

June 13, 2025

Vol.51 No.23

Cancer Policy

FDA rolls out agency-wide AI tool

FDA rolled out a generative artificial intelligence tool designed to help employees across the agency “work more efficiently.”

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Drugs & Targets

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.

June 06, 2025

Vol.51 No.22

MD Anderson, Exscientia collaborate to develop oncology treatments using AI

YOU MAY BE INTERESTED IN

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

SU2C, SandboxAQ collaborate to accelerate treatment innovation

FDA rolls out agency-wide AI tool

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Renew today!

Subscriber content

Never miss an issue!

Login